Referenser

  1. Axelsson KF, Litsne H, Harvey NC, Kanis JA, McCloskey E, Johansson H, et al. Revised Swedish FRAX models and the establishment of age-dependent intervention thresholds. Osteoporosis Int. 2026
  2. Willers C, Norton N, Harvey NC, Jacobson T, Johansson H, Lorentzon M, et al. Osteoporosis in Europe: a compendium of country-specific reports. Arch Osteoporos. 2022;17(1):23
  3. Socialstyrelsen. Nationella riktlinjer för rörelseorganens sjukdomar. Reumatoid artrit, axial spondylartrit, psoriasisartrit, artros och osteoporos.: Socialstyrelsen; 2021 2021. Report No.: 978-91-7555-551-5
  4. Läkemedelsverket. Läkemedel vid osteoporos för att förhindra benskörhetsfrakturer – behandlings­rekommendation 2020 [cited 2020. Available from: https://www.lakemedelsverket.se/sv/behandling-och-forskrivning/behandlingsrekommendationer/sok-behandlingsrekommendationer/lakemedel-vid-osteoporos-for-att-forhindra-benskorhetsfrakturer—behandlingsrekommendation#hmainbody1
  5. (SKR) SKoR. Osteoporos. Ett personcentrerat och sammanhållet vårdförlopp är framtaget för osteoporos – sekundärprevention efter fraktur.: Sveriges Kommuner och Regioner (SKR); 2020
  6. Ek S, Meyer AC, Sääf M, Hedström M, Modig K. Secondary fracture prevention with osteoporosis medication after a fragility fracture in Sweden remains low despite new guidelines. Arch Osteoporos. 2023;18(1):107
  7. Axelsson KF, Johansson H, Lundh D, Möller M, Lorentzon M. Association Between Recurrent Fracture Risk and Implementation of Fracture Liaison Services in Four Swedish Hospitals: A Cohort Study. J Bone Miner Res. 2020
  8. Force USPST, Nicholson WK, Silverstein M, Wong JB, Chelmow D, Coker TR, et al. Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement. JAMA. 2025;333(6):498–508.
  9. McCloskey EV, Chotiyarnwong P, Harvey NC, Lorentzon M, Kanis JA. Population screening for fracture risk in postmenopausal women – a logical step in reducing the osteoporotic fracture burden? Osteoporos Int. 2022;33(8):1631–7
  10. McCloskey EV, Harvey NC, Johansson H, Lorentzon M, Liu E, Vandenput L, et al. Fracture risk assessment by the FRAX model. Climacteric. 2022;25(1):22–8
  11. Leslie WD, Schousboe JT, Morin SN, Martineau P, Lix LM, Johansson H, et al. Fracture risk following high-trauma versus low-trauma fracture: a registry-based cohort study. Osteoporos Int. 2020;31(6):1059–67
  12. Mackey DC, Lui LY, Cawthon PM, Bauer DC, Nevitt MC, Cauley JA, et al. High-trauma fractures and low bone mineral density in older women and men. Jama. 2007;298(20):2381–8
  13. Lorentzon M, Florberger C, Merina J, Bertholds E, Litsne H, Axelsson KF. Osteoporosis treatment indications following fracture: identifying relevant fracture sites for Fracture Liaison Services. Arch Osteoporos. 2026;21(1)
  14. Axelsson KF, Litsne H, Lorentzon M. The Importance of Recent Prevalent Fracture Site for Imminent Risk of Fracture – A Retrospective, Nationwide Cohort Study of Older Swedish Men and Women. J Bone Miner Res. 2023;38(6):851–9
  15. Gregson CL, Armstrong DJ, Avgerinou C, Bowden J, Cooper C, Douglas L, et al. The 2024 UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2025;20(1):119
  16. Larsson BAM, Johansson L, Johansson H, Axelsson KF, Harvey N, Vandenput L, et al. The timed up and go test predicts fracture risk in older women independently of clinical risk factors and bone mineral density. Osteoporos Int. 2021;32(1):75–84
  17. Larsson BAM, Johansson L, Mellström D, Johansson H, Axelsson KF, Harvey N, et al. One leg standing time predicts fracture risk in older women independent of clinical risk factors and BMD. Osteoporos Int. 2022;33(1):185–94
  18. Lim Y, Ha J, Yoon KH, Baek KH, Kang MI. Measures of physical performance as a predictor of fracture risk independent of BMD: The Chungju metabolic disease cohort study. Bone. 2021;145:115878
  19. ISCD. 2023 ISCD Official Positions Adult. 2023
  20. Ebeling PR, Nguyen HH, Aleksova J, Vincent AJ, Wong P, Milat F. Secondary Osteoporosis. Endocrine Reviews. 2021;43(2):240–313
  21. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13(10):777–87
  22. Laan RF, van Riel PL, van de Putte LB, van Erning LJ, van’t Hof MA, Lemmens JA. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med. 1993;119(10):963–8
  23. Angeli A, Guglielmi G, Dovio A, Capelli G, de Feo D, Giannini S, et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone. 2006;39(2):253–9
  24. Weinstein RS. Is long-term glucocorticoid therapy associated with a high prevalence of asymptomatic vertebral fractures? Nat Clin Pract Endocrinol Metab. 2007;3(2):86–7
  25. Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009;373(9671):1253–63
  26. Homik J, Suarez-Almazor ME, Shea B, Cranney A, Wells G, Tugwell P. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev. 2000;1998(2):Cd000952
  27. Humphrey MB, Russell L, Danila MI, Fink HA, Guyatt G, Cannon M, et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Care Res (Hoboken). 2023;75(12):2405–19
  28. Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol. 2017;69(8):1521–37
  29. Malmgren L, McGuigan FE, Christensson A, Akesson KE. Longitudinal Changes in Kidney Function Estimated from Cystatin C and Its Association with Mortality in Elderly Women. Nephron. 2020;144(6):290–8
  30. Evenepoel P, Cunningham J, Ferrari S, Haarhaus M, Javaid MK, Lafage-Proust MH, et al. European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4-G5D. Nephrol Dial Transplant. 2021;36(1):42–59
  31. Ginsberg C, Ix JH. Diagnosis and Management of Osteoporosis in Advanced Kidney Disease: A Review. American Journal of Kidney Diseases. 2022;79(3):427–36
  32. Jamal SA, Ljunggren O, Stehman-Breen C, Cummings SR, McClung MR, Goemaere S, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res. 2011;26(8):1829–35
  33. Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res. 2005;20(12):2105–15
  34. Bird ST, Gelperin K, Smith ER, Jung TH, Lyu H, Thompson A, et al. The Effect of Denosumab on Risk for Emergently Treated Hypocalcemia by Stage of Chronic Kidney Disease : A Target Trial Emulation. Ann Intern Med. 2025;178(1):29–38
  35. Sun X, Bolster MB, Leder BZ, Fan W. Dose-Specific Effects of Denosumab on Serum Calcium Levels in Patients With Osteoporosis and Various Renal Functions. J Clin Endocrinol Metab. 2025;110(7):1915–22
  36. Abdalbary M, Amin AM, Elaraby A, Hassan A. Efficacy and safety of romosozumab in patients with chronic kidney disease and osteoporosis: a narrative review. Osteoporos Int. 2026;37(2):319–29
  37. Rodman JS, Mahler RJ. KIDNEY STONES AS A MANIFESTATION OF HYPERCALCEMIC DISORDERS: Hyperparathyroidism and Sarcoidosis. Urologic Clinics of North America. 2000;27(2):275–85
  38. Axelsson KF, Wallander M, Johansson H, Harvey NC, Vandenput L, McCloskey E, et al. Analysis of Comorbidities, Clinical Outcomes, and Parathyroidectomy in Adults With Primary Hyperparathyroidism. JAMA Netw Open. 2022;5(6):e2215396
  39. Samverkan SKi. Nationellt vårdprogram för primär hyperparatyreoidism. 2023
  40. Bilezikian JP, Khan AA, Silverberg SJ, Fuleihan GE, Marcocci C, Minisola S, et al. Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop. J Bone Miner Res. 2022;37(11):2293–314
  41. Chow CC, Chan WB, Li JK, Chan NN, Chan MH, Ko GT, et al. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 2003;88(2):581–7
  42. Leere JS, Karmisholt J, Robaczyk M, Lykkeboe S, Handberg A, Steinkohl E, et al. Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2020;8(5):407–17
  43. Rajput S, Dutta A, Rajender S, Mithal A, Chattopadhyay N. Efficacy of antiresorptive agents bisphosphonates and denosumab in mitigating hypercalcemia and bone loss in primary hyperparathyroidism: A systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023;14:1098841
  44. Hoong CWS, Saul D, Khosla S, Sfeir JG. Advances in the management of osteoporosis. Bmj. 2025;390:e081250
  45. Black DM, Cauley JA, Wagman R, Ensrud K, Fink HA, Hillier TA, et al. The Ability of a Single BMD and Fracture History Assessment to Predict Fracture Over 25 Years in Postmenopausal Women: The Study of Osteoporotic Fractures. J Bone Miner Res. 2018;33(3):389–95
  46. Socialstyrelsen. Klimakteriebesvär. Prioriteringsstöd till dig som beslutar om resurser i hälso- och sjukvården.; 2025
  47. Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, et al. Effects of Estrogen Plus Progestin on Risk of Fracture and Bone Mineral DensityThe Women’s Health Initiative Randomized Trial. JAMA. 2003;290(13):1729–38
  48. Bolland MJ, Nisa Z, Mellar A, Gasteiger C, Pinel V, Mihov B, et al. Fracture Prevention with Infrequent Zoledronate in Women 50 to 60 Years of Age. N Engl J Med. 2025;392(3):239–48
  49. Lorentzon M, Johansson H, Harvey NC, Liu E, Vandenput L, Crandall CJ, et al. Menopausal hormone therapy reduces the risk of fracture regardless of falls risk or baseline FRAX probability-results from the Women’s Health Initiative hormone therapy trials. Osteoporos Int. 2022;33(11):2297–305
  50. 2019 surveillance of menopause: diagnosis and management (NICE guideline NG23). London: National Institute for Health and Care Excellence (NICE)
  51. Rozenberg S, Al-Daghri N, Aubertin-Leheudre M, Brandi ML, Cano A, Collins P, et al. Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis? Osteoporos Int. 2020;31(12):2271–86
  52. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809–22
  53. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab. 2000;85(11):4118–24
  54. Lorentzon M. Treating osteoporosis to prevent fractures: current concepts and future developments. J ntern Med . 2019;285(4):381–94
  55. Bastounis A, Langley T, Davis S, Paskins Z, Gittoes N, Leonardi-Bee J, et al. Comparing medication adherence in patients receiving bisphosphonates for preventing fragility fractures: a comprehensive systematic review and network meta-analysis. Osteoporos Int. 2022;33(6):1223–33
  56. Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012;27(2):243–54
  57. Reid IR, Horne A, Mihov B, Stewart A, Garratt E, Wong S, et al. Fracture Prevention with Zoledronate in Older Women with Osteopenia. The New England Joural of Medicine. 2018:1–10
  58. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–65
  59. Miller PD, Pannacciulli N, Brown JP, Czerwinski E, Nedergaard BS, Bolognese MA, et al. Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates. J Clin Endocrinol Metab. 2016;101(8):3163–70
  60. Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513–23
  61. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927–38
  62. Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med. 2017;377(15):1417–27
  63. Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018;391(10117):230–40
  64. Cosman F, Kendler DL, Langdahl BL, Leder BZ, Lewiecki EM, Miyauchi A, et al. Romosozumab and antiresorptive treatment: the importance of treatment sequence. Osteoporos Int. 2022;33(6):1243–56
  65. Miller PD, Delmas PD, Lindsay R, Watts NB, Luckey M, Adachi J, et al. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab. 2008;93(10):3785–93
  66. Black DM, Bouxsein ML, Bauer DC, Eastell R. Bone mineral density as a surrogate biomarker for fracture risk reduction – Authors’ reply. Lancet Diabetes Endocrinol. 2020;8(11):876
  67. Sekar V. BIOMARKER QUALIFICATION PROGRAM (BQP). FULL QUALIFICATION PACKAGE (FQP) INTEGRATED REVIEW. Food and Drug Administration; 2025 December 19, 2025
  68. Diez-Perez A, Adachi JD, Agnusdei D, Bilezikian JP, Compston JE, Cummings SR, et al. Treatment failure in osteoporosis. Osteoporos Int. 2012;23(12):2769–74
  69. Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet. 2015;386(9999):1147–55
  70. Cosman F, Lewiecki EM, Eastell R, Ebeling PR, Jan De Beur S, Langdahl B, et al. Goal-directed osteoporosis treatment: ASBMR/BHOF task force position statement 2024. Journal of Bone and Mineral Research. 2024;39(10):1393–405
  71. Ferrari S, Libanati C, Lin CJF, Brown J, Cosman F, Czerwiński E, et al. Relationship Between Bone Mineral Density T‐Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment. Journal of Bone and Mineral Research. 2019;34(6):1033–40
  72. Kendler DL, Cosman F, Stad RK, Ferrari S. Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review. Adv Ther. 2022;39(1):58–74
  73. Cosman F, Crittenden DB, Ferrari S, Lewiecki EM, Jaller-Raad J, Zerbini C, et al. Romosozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome. J Bone Miner Res. 2018;33(8):1407–16
  74. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22(10):1479–91
  75. Black DM, Geiger EJ, Eastell R, Vittinghoff E, Li BH, Ryan DS, et al. Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates. N Engl J Med. 2020;383(8):743–53
  76. Gedmintas L, Solomon DH, Kim SC. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res. 2013;28(8):1729–37
  77. Liu CJ, Latham NK. Progressive resistance strength training for improving physical function in older adults. Cochrane Database Syst Rev. 2009;2009(3):Cd002759
  78. Sherrington C, Fairhall NJ, Wallbank GK, Tiedemann A, Michaleff ZA, Howard K, et al. Exercise for preventing falls in older people living in the community. Cochrane Database of Systematic Reviews. 2019(1)
  79. Lee SY, Jung SH, Lee SU, Ha YC, Lim JY. Effect of Balance Training After Hip Fracture Surgery: A Systematic Review and Meta-analysis of Randomized Controlled Studies. J Gerontol A Biol Sci Med Sci. 2019;74(10):1679–85
  80. Sherrington C, Fairhall N, Wallbank G, Tiedemann A, Michaleff ZA, Howard K, et al. Exercise for preventing falls in older people living in the community: an abridged Cochrane systematic review. Br J Sports Med. 2020;54(15):885–91
  81. Fabiani R, Naldini G, Chiavarini M. Dietary Patterns in Relation to Low Bone Mineral Density and Fracture Risk: A Systematic Review and Meta-Analysis. Advances in Nutrition. 2019;10(2):219–36
  82. De Laet C, Kanis JA, Odén A, Johanson H, Johnell O, Delmas P, et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int. 2005;16(11):1330–8
  83. Socialstyrelsen. Insatser vid riskbruk av alkohol. Rekommendationer till hälso- och sjukvården och tandvården. Socialstyrelsen; 2024. p. 1–6
  84. Vescini F, Chiodini I, Falchetti A, Palermo A, Salcuni AS, Bonadonna S, et al. Management of Osteoporosis in Men: A Narrative Review. Int J Mol Sci. 2021;22(24)
  85. Wallander M, Axelsson KF, Lundh D, Lorentzon M. Patients with prostate cancer and androgen deprivation therapy have increased risk of fractures-a study from the fractures and fall injuries in the elderly cohort (FRAILCO). Osteoporos Int. 2019;30(1):115–25
  86. Rinonapoli G, Ruggiero C, Meccariello L, Bisaccia M, Ceccarini P, Caraffa A. Osteoporosis in Men: A Review of an Underestimated Bone Condition. Int J Mol Sci. 2021;22(4)
  87. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000;343(9):604–10
  88. Orwoll E, Scheele W, Paul S, Adami S, Syversen U, Diez‐Perez A, et al. The Effect of Teriparatide [Human Parathyroid Hormone (1–34)] Therapy on Bone Density in Men With Osteoporosis*. Journal of Bone and Mineral Research. 2009;18(1):9–17
  89. Orwoll E, Teglbjærg CS, Langdahl BL, Chapurlat R, Czerwinski E, Kendler DL, et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab. 2012;97(9):3161–9.
  90. Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res. 2009;24(4):719–25
  91. Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J, Langdahl B, et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med. 2012;367(18):1714–23
  92. Osteoporosis prevention, diagnosis, and therapy. Jama. 2001;285(6):785–95
  93. Siris ES, Adler R, Bilezikian J, Bolognese M, Dawson-Hughes B, Favus MJ, et al. The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int. 2014;25(5):1439–43

Senast ändrad: 30 maj 2026

info@svos.se

Snabblänkar

Vårdprogram